Par Pharmaceutical has launched an advanced formulation of megestrol acetate, Megace ES 625 mg/5 ml (megestrol acetate) oral suspension. Megace ES is indicated for the treatment of anorexia, cachexia, or a significant, unexplained weight loss in patients with a diagnosis of AIDS.
Par launches advanced formulation of Megace ES
Par Pharmaceutical has launched an advanced formulation of megestrol acetate, Megace ES 625 mg/5 ml (megestrol acetate) oral suspension. Megace ES is indicated for the treatment of anorexia, cachexia, or a significant, unexplained weight loss in patients with a diagnosis of AIDS.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.